← Back to headlines
Valneva Outlines 2026 Revenue Guidance, Pfizer Targets Lyme Decisions
Valneva has outlined its 2026 revenue guidance between $145 million and $160 million, while Pfizer aims to make decisions regarding its Lyme disease initiatives within the next 12 months.
14 Aug, 02:30 — 14 Aug, 02:30
Sources
Showing 1 of 1 sources
Related Stories
HDFC Bank CEO Sashidhar Jagdishan to Step Down in October
1h ago
FSSAI Bans Everest and Laljee Godhoo From Selling Substandard Hing Powder
2h ago
UAE Central Bank Launches Probe Into Banque Misr Over US Money Laundering Warnings
3h ago
S&P, Nasdaq end lower after Fed Chair Warsh reaffirms inflation fight - Reuters
3h ago